BridgeBio Pharma, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $314.74M, a 120.07% increase year-over-year.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $305.76M.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $1.03M.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for the quarter ending 2023-03-31 was $143.02M.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for fiscal 2024 was $314.74M, a 30.03% decline from fiscal 2023.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for fiscal 2023 was $449.81M, a 9170.61% increase from fiscal 2022.
- BridgeBio Pharma, Inc. stock issued during period, value, new issues for fiscal 2022 was $4.85M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2024-12-31 | $314.74M 10-K · filed 2026-02-24 | |
| 2024-03-31 | $314.74M 10-Q · filed 2025-10-29 | |
| 2023-12-31 | $449.81M 10-K · filed 2026-02-24 | |
| 2023-09-30 | $305.76M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $1.03M 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $143.02M 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $4.85M 10-K · filed 2025-02-20 | |
| 2019-09-30 | $366.24M 10-Q · filed 2019-11-08 | |
| 2018-06-30 | $36.30M 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |